J. Goldman & CO LP Amylyx Pharmaceuticals, Inc. Call Options Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$2.71 - $19.57 $57,181 - $412,927	-21,100 Reduced 28.13%	53,900 $153,000
Q4 2023 Feb 14, 2024	BUY	$12.07 - $18.46 $543,150 - $830,700	45,000 Added 150.0%	75,000 $1.1 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $62,940 - $94,260	3,000 Added 11.11%	30,000 $647,000
Q1 2023 May 15, 2023	SELL	$27.71 - $40.93 $750,941 - $1.11 Million	-27,100 Reduced 50.09%	27,000 $792,000
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $1.61 Million - $2.12 Million	54,100 New	54,100 $2 Million

139

46.5M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $290M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.